We were delighted to meet with Martin Hoenigl (University of California San Diego & Medical University of Graz, Graz, Austria) to discuss the current challenges in treating invasive candida infections.
The abstract entitled: ‘Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase III open-label study (FURI)’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Question:
- Could you give us a brief overview of the current challenges in treating invasive Candida infections? (0:22)
Disclosures: Martin Hoenigl has received research support from Gilead, Astellas, Pfizer, Scynexis, F2G and NIH.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
